SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '2gcd'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IGX_A_EPAA700_2
(PROSTAGLANDIN
ENDOPEROXIDE H
SYNTHASE-1)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		4 / 8 VAL A  53
TYR A 107
SER A 160
ILE A 294
 None
STU  A 400 (-4.5A)
None
None
 0.88A 1igxA-2gcdA:
undetectable		 1igxA-2gcdA:
20.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1JGS_A_SALA256_1
(MULTIPLE ANTIBIOTIC
RESISTANCE PROTEIN
MARR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		4 / 7 VAL A 131
LEU A 218
THR A 214
LEU A 211
 None
 0.76A 1jgsA-2gcdA:
undetectable		 1jgsA-2gcdA:
20.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWH_A_BAXA1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 ALA A  55
GLU A  76
CYH A 108
LEU A 142
HIS A 149
GLY A 168
 STU  A 400 (-3.2A)
None
STU  A 400 (-4.0A)
None
None
None
 0.71A 1uwhA-2gcdA:
25.8		 1uwhA-2gcdA:
31.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWH_A_BAXA1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 ALA A  55
GLU A  76
LEU A  80
LEU A 142
HIS A 149
GLY A 168
 STU  A 400 (-3.2A)
None
None
None
None
None
 0.84A 1uwhA-2gcdA:
25.8		 1uwhA-2gcdA:
31.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWH_B_BAXB1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ALA A  55
LYS A  57
GLU A  76
CYH A 108
LEU A 142
HIS A 149
GLY A 168
 STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 (-4.0A)
None
None
None
 0.78A 1uwhB-2gcdA:
25.6		 1uwhB-2gcdA:
31.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWH_B_BAXB1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ALA A  55
LYS A  57
GLU A  76
LEU A  80
LEU A 142
HIS A 149
GLY A 168
 STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
None
None
None
None
 0.90A 1uwhB-2gcdA:
25.6		 1uwhB-2gcdA:
31.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWJ_A_BAXA1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 VAL A  42
ALA A  55
GLU A  76
CYH A 108
LEU A 142
HIS A 149
GLY A 168
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
None
STU  A 400 (-4.0A)
None
None
None
 0.75A 1uwjA-2gcdA:
7.9		 1uwjA-2gcdA:
31.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWJ_B_BAXB1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		8 / 12 ILE A  34
VAL A  42
ALA A  55
GLU A  76
CYH A 108
LEU A 142
HIS A 149
GLY A 168
 STU  A 400 (-4.2A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
None
STU  A 400 (-4.0A)
None
None
None
 0.86A 1uwjB-2gcdA:
8.0		 1uwjB-2gcdA:
31.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XBB_A_STIA1_1
(TYROSINE-PROTEIN
KINASE SYK)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 9 VAL A  42
ALA A  55
MET A 105
GLY A 110
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 3.7A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.44A 1xbbA-2gcdA:
28.4		 1xbbA-2gcdA:
25.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2EVA_A_ADNA498_1
(TAK1 KINASE - TAB1
CHIMERA FUSION
PROTEIN)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 11 GLY A  35
VAL A  42
ALA A  55
MET A 105
TYR A 107
SER A 111
LEU A 158
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 3.7A)
STU  A 400 (-4.5A)
STU  A 400 (-3.3A)
STU  A 400 ( 4.6A)
 0.47A 2evaA-2gcdA:
25.7		 2evaA-2gcdA:
30.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FUM_A_MIXA539_1
(PROBABLE
SERINE/THREONINE-PRO
TEIN KINASE PKNB)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 GLY A  35
VAL A  42
ALA A  55
ASP A 151
LYS A 153
ASN A 156
ASP A 169
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
None
None
STU  A 400 (-4.4A)
STU  A 400 (-3.6A)
 0.75A 2fumA-2gcdA:
28.6		 2fumA-2gcdA:
27.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FUM_B_MIXB1539_1
(PROBABLE
SERINE/THREONINE-PRO
TEIN KINASE PKNB)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		8 / 12 GLY A  35
VAL A  42
ALA A  55
MET A 105
TYR A 107
LYS A 153
ASN A 156
ASP A 169
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 3.7A)
STU  A 400 (-4.5A)
None
STU  A 400 (-4.4A)
STU  A 400 (-3.6A)
 0.77A 2fumB-2gcdA:
28.6		 2fumB-2gcdA:
27.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FUM_C_MIXC2539_1
(PROBABLE
SERINE/THREONINE-PRO
TEIN KINASE PKNB)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 GLY A  35
VAL A  42
ALA A  55
MET A 105
TYR A 107
ASN A 156
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 3.7A)
STU  A 400 (-4.5A)
STU  A 400 (-4.4A)
 0.49A 2fumC-2gcdA:
27.3		 2fumC-2gcdA:
27.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FUM_D_MIXD3539_1
(PROBABLE
SERINE/THREONINE-PRO
TEIN KINASE PKNB)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 GLY A  35
GLY A  37
VAL A  42
ALA A  55
MET A 105
ASN A 156
 STU  A 400 (-3.3A)
None
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 3.7A)
STU  A 400 (-4.4A)
 0.58A 2fumD-2gcdA:
27.5		 2fumD-2gcdA:
27.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FUM_D_MIXD3539_1
(PROBABLE
SERINE/THREONINE-PRO
TEIN KINASE PKNB)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 GLY A  35
VAL A  42
ALA A  55
MET A 105
LYS A 153
ASN A 156
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 3.7A)
None
STU  A 400 (-4.4A)
 0.55A 2fumD-2gcdA:
27.5		 2fumD-2gcdA:
27.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 GLY A  35
VAL A  42
LYS A  57
GLU A  76
LEU A  80
LEU A 103
TYR A 107
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 ( 4.5A)
None
None
None
STU  A 400 (-4.5A)
 0.75A 2ivuA-2gcdA:
28.2		 2ivuA-2gcdA:
27.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2JFA_B_RALB600_2
(ESTROGEN RECEPTOR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		4 / 4 LEU A 167
THR A  88
ILE A 148
HIS A 143
 None
 1.32A 2jfaB-2gcdA:
undetectable		 2jfaB-2gcdA:
20.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2OIQ_A_STIA1001_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 VAL A  42
ALA A  55
LYS A  57
GLU A  76
TYR A 107
GLY A 110
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 (-4.5A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.55A 2oiqA-2gcdA:
25.2		 2oiqA-2gcdA:
30.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2OTF_A_2TNA201_1
(PHOSPHOLIPASE A2
VRV-PL-VIIIA)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		4 / 5 LEU A 211
ILE A 157
GLY A 138
HIS A 143
 None
 0.88A 2otfA-2gcdA:
undetectable		 2otfA-2gcdA:
14.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WGJ_A_VGHA2346_1
(HEPATOCYTE GROWTH
FACTOR RECEPTOR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 GLY A  35
VAL A  42
ALA A  55
TYR A 107
GLY A 110
ASP A 169
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-4.5A)
STU  A 400 (-3.4A)
STU  A 400 (-3.6A)
 0.74A 2wgjA-2gcdA:
25.8		 2wgjA-2gcdA:
27.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XN7_A_T44A1355_1
(THYROXINE-BINDING
GLOBULIN)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 10 ALA A 154
LEU A 293
SER A 113
LEU A 123
ARG A 221
 None
None
STU  A 400 ( 4.7A)
None
None
 1.09A 2xn7A-2gcdA:
undetectable
2xn7B-2gcdA:
undetectable		 2xn7A-2gcdA:
22.13
2xn7B-2gcdA:
8.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XP2_A_VGHA9000_1
(TYROSINE-PROTEIN
KINASE RECEPTOR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 9 VAL A  42
ALA A  55
GLY A 110
LEU A 158
GLY A 168
ASP A 169
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
None
STU  A 400 (-3.6A)
 0.68A 2xp2A-2gcdA:
8.7		 2xp2A-2gcdA:
28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y7J_A_B49A1294_1
(PHOSPHORYLASE B
KINASE GAMMA
CATALYTIC CHAIN,
TESTIS/LIVER ISOFORM)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 ILE A  34
VAL A  42
ALA A  55
ILE A  89
GLY A 110
LEU A 158
 STU  A 400 (-4.2A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.44A 2y7jA-2gcdA:
30.6		 2y7jA-2gcdA:
23.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y7J_B_B49B1294_1
(PHOSPHORYLASE B
KINASE GAMMA
CATALYTIC CHAIN,
TESTIS/LIVER ISOFORM)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 10 ILE A  34
VAL A  42
ALA A  55
ILE A  89
GLY A 110
LEU A 158
 STU  A 400 (-4.2A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.56A 2y7jB-2gcdA:
31.2		 2y7jB-2gcdA:
23.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y7J_C_B49C1294_1
(PHOSPHORYLASE B
KINASE GAMMA
CATALYTIC CHAIN,
TESTIS/LIVER ISOFORM)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 10 ILE A  34
VAL A  42
ALA A  55
ILE A  89
GLY A 110
LEU A 158
 STU  A 400 (-4.2A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.53A 2y7jC-2gcdA:
30.7		 2y7jC-2gcdA:
23.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y7J_D_B49D1294_1
(PHOSPHORYLASE B
KINASE GAMMA
CATALYTIC CHAIN,
TESTIS/LIVER ISOFORM)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 10 ILE A  34
VAL A  42
ALA A  55
ILE A  89
GLY A 110
LEU A 158
 STU  A 400 (-4.2A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.60A 2y7jD-2gcdA:
30.7		 2y7jD-2gcdA:
23.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2YFX_A_VGHA9000_1
(TYROSINE-PROTEIN
KINASE RECEPTOR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 8 ALA A  55
MET A 105
GLY A 110
LEU A 158
GLY A 168
ASP A 169
 STU  A 400 (-3.2A)
STU  A 400 ( 3.7A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
None
STU  A 400 (-3.6A)
 0.55A 2yfxA-2gcdA:
18.4		 2yfxA-2gcdA:
28.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3EYG_A_MI1A1_1
(TYROSINE-PROTEIN
KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		8 / 12 GLY A  35
VAL A  42
ALA A  55
MET A 105
SER A 111
ASN A 156
LEU A 158
ASP A 169
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 3.7A)
STU  A 400 (-3.3A)
STU  A 400 (-4.4A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.65A 3eygA-2gcdA:
26.6		 3eygA-2gcdA:
29.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3FUP_A_MI1A1_1
(TYROSINE-PROTEIN
KINASE JAK2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		8 / 12 GLY A  35
GLY A  37
GLY A  40
VAL A  42
ALA A  55
LYS A  57
MET A 105
TYR A 107
 STU  A 400 (-3.3A)
None
None
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 ( 3.7A)
STU  A 400 (-4.5A)
 0.78A 3fupA-2gcdA:
26.4		 3fupA-2gcdA:
30.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3FUP_A_MI1A1_1
(TYROSINE-PROTEIN
KINASE JAK2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		8 / 12 GLY A  35
VAL A  42
ALA A  55
LYS A  57
MET A 105
TYR A 107
SER A 111
LEU A 158
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 ( 3.7A)
STU  A 400 (-4.5A)
STU  A 400 (-3.3A)
STU  A 400 ( 4.6A)
 0.78A 3fupA-2gcdA:
26.4		 3fupA-2gcdA:
30.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3FUP_A_MI1A1_1
(TYROSINE-PROTEIN
KINASE JAK2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		8 / 12 GLY A  35
VAL A  42
ALA A  55
MET A 105
TYR A 107
SER A 111
LEU A 158
ASP A 169
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 3.7A)
STU  A 400 (-4.5A)
STU  A 400 (-3.3A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.80A 3fupA-2gcdA:
26.4		 3fupA-2gcdA:
30.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3FUP_B_MI1B1_1
(TYROSINE-PROTEIN
KINASE JAK2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		8 / 12 GLY A  35
GLY A  37
VAL A  42
ALA A  55
LYS A  57
MET A 105
TYR A 107
LEU A 158
 STU  A 400 (-3.3A)
None
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 ( 3.7A)
STU  A 400 (-4.5A)
STU  A 400 ( 4.6A)
 0.52A 3fupB-2gcdA:
26.2		 3fupB-2gcdA:
30.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3G0E_A_B49A9000_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 11 VAL A  42
ALA A  55
TYR A 107
CYH A 108
GLY A 110
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-4.5A)
STU  A 400 (-4.0A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.44A 3g0eA-2gcdA:
23.3		 3g0eA-2gcdA:
26.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3G0F_A_B49A9001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 11 VAL A  42
ALA A  55
TYR A 107
CYH A 108
GLY A 110
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-4.5A)
STU  A 400 (-4.0A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.52A 3g0fA-2gcdA:
24.0		 3g0fA-2gcdA:
26.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3G0F_B_B49B9001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 10 VAL A  42
ALA A  55
TYR A 107
CYH A 108
GLY A 110
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-4.5A)
STU  A 400 (-4.0A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.46A 3g0fB-2gcdA:
24.9		 3g0fB-2gcdA:
26.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3HEG_A_BAXA1_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 12 VAL A  42
ALA A  55
LYS A  57
GLU A  76
LEU A  80
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
None
 0.79A 3hegA-2gcdA:
22.6		 3hegA-2gcdA:
26.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LXK_A_MI1A1125_1
(TYROSINE-PROTEIN
KINASE JAK3)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 GLY A  35
VAL A  42
ALA A  55
LYS A  57
MET A 105
TYR A 107
LEU A 158
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 ( 3.7A)
STU  A 400 (-4.5A)
STU  A 400 ( 4.6A)
 0.76A 3lxkA-2gcdA:
26.5		 3lxkA-2gcdA:
26.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LXN_A_MI1A1_1
(NON-RECEPTOR
TYROSINE-PROTEIN
KINASE TYK2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 GLY A  35
VAL A  42
ALA A  55
ILE A  89
TYR A 107
SER A 111
LEU A 158
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 (-4.5A)
STU  A 400 (-3.3A)
STU  A 400 ( 4.6A)
 0.42A 3lxnA-2gcdA:
26.9		 3lxnA-2gcdA:
32.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LXN_A_MI1A1_1
(NON-RECEPTOR
TYROSINE-PROTEIN
KINASE TYK2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 GLY A  35
VAL A  42
ALA A  55
LYS A  57
ILE A  89
TYR A 107
LEU A 158
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 ( 4.5A)
STU  A 400 (-4.5A)
STU  A 400 ( 4.6A)
 0.56A 3lxnA-2gcdA:
26.9		 3lxnA-2gcdA:
32.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_A_STIA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 VAL A  42
ALA A  55
GLU A  76
TYR A 107
GLY A 110
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
None
STU  A 400 (-4.5A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.55A 3oezA-2gcdA:
25.3		 3oezA-2gcdA:
30.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OHT_B_1N1B1000_1
(P38A)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 GLY A  35
VAL A  42
ALA A  55
LYS A  57
LEU A  80
GLY A 110
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 (-3.4A)
 0.64A 3ohtB-2gcdA:
18.4		 3ohtB-2gcdA:
24.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RGF_A_BAXA465_1
(CYCLIN-DEPENDENT
KINASE 8)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 VAL A  42
ALA A  55
GLU A  76
ILE A  89
TYR A 107
LEU A 142
HIS A 149
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
None
STU  A 400 ( 4.5A)
STU  A 400 (-4.5A)
None
None
 0.72A 3rgfA-2gcdA:
8.1		 3rgfA-2gcdA:
24.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RGF_A_BAXA465_1
(CYCLIN-DEPENDENT
KINASE 8)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 VAL A  42
ALA A  55
GLU A  76
LEU A  80
TYR A 107
LEU A 142
HIS A 149
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
None
None
STU  A 400 (-4.5A)
None
None
 0.65A 3rgfA-2gcdA:
8.1		 3rgfA-2gcdA:
24.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UWL_D_FOZD316_0
(THYMIDYLATE SYNTHASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 12 LEU A 164
LEU A 123
GLY A 110
ILE A 157
ALA A 154
 None
None
STU  A 400 (-3.4A)
None
None
 1.04A 3uwlD-2gcdA:
undetectable		 3uwlD-2gcdA:
21.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3V5W_A_8PRA701_1
(G-PROTEIN COUPLED
RECEPTOR KINASE 2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 ILE A  34
GLY A  37
GLY A  40
VAL A  42
ALA A  55
ASP A 169
 STU  A 400 (-4.2A)
None
None
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-3.6A)
 0.64A 3v5wA-2gcdA:
11.1		 3v5wA-2gcdA:
20.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3V5W_A_8PRA701_1
(G-PROTEIN COUPLED
RECEPTOR KINASE 2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 ILE A  34
GLY A  37
GLY A  40
VAL A  42
ALA A  55
LYS A  57
 STU  A 400 (-4.2A)
None
None
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
 0.67A 3v5wA-2gcdA:
11.1		 3v5wA-2gcdA:
20.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WZE_A_BAXA1201_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 VAL A  42
ALA A  55
GLU A  76
LEU A  80
GLY A 110
LEU A 142
HIS A 149
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
None
None
STU  A 400 (-3.4A)
None
None
 0.68A 3wzeA-2gcdA:
24.2		 3wzeA-2gcdA:
27.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3ZBF_A_VGHA3000_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ROS)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 12 ALA A  55
GLY A 110
LEU A 158
GLY A 168
ASP A 169
 STU  A 400 (-3.2A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
None
STU  A 400 (-3.6A)
 0.52A 3zbfA-2gcdA:
21.4		 3zbfA-2gcdA:
29.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3ZOS_B_0LIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ALA A  55
GLU A  76
ILE A  89
LEU A 142
HIS A 149
ARG A 150
LEU A 158
 STU  A 400 (-3.2A)
None
STU  A 400 ( 4.5A)
None
None
SEP  A 181 ( 2.9A)
STU  A 400 ( 4.6A)
 0.67A 3zosB-2gcdA:
24.1		 3zosB-2gcdA:
28.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AGC_A_AXIA2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 VAL A  42
ALA A  55
GLU A  76
LEU A  80
GLY A 110
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
None
None
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.58A 4agcA-2gcdA:
24.0		 4agcA-2gcdA:
26.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ASD_A_BAXA1500_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 VAL A  42
ALA A  55
GLU A  76
LEU A  80
GLY A 110
LEU A 142
HIS A 149
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
None
None
STU  A 400 (-3.4A)
None
None
 0.58A 4asdA-2gcdA:
24.1		 4asdA-2gcdA:
26.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4BKJ_B_STIB1000_2
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		4 / 5 LYS A  57
LEU A  83
TYR A 107
ARG A 150
 STU  A 400 ( 4.5A)
None
STU  A 400 (-4.5A)
SEP  A 181 ( 2.9A)
 1.02A 4bkjB-2gcdA:
24.4		 4bkjB-2gcdA:
28.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CKI_A_ADNA2022_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 11 GLY A  35
VAL A  42
ALA A  55
TYR A 107
GLY A 110
SER A 111
LEU A 158
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-4.5A)
STU  A 400 (-3.4A)
STU  A 400 (-3.3A)
STU  A 400 ( 4.6A)
 0.59A 4ckiA-2gcdA:
28.2		 4ckiA-2gcdA:
26.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CKJ_A_ADNA2014_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 10 GLY A  35
GLY A  37
VAL A  42
ALA A  55
TYR A 107
SER A 111
LEU A 158
 STU  A 400 (-3.3A)
None
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-4.5A)
STU  A 400 (-3.3A)
STU  A 400 ( 4.6A)
 0.65A 4ckjA-2gcdA:
28.3		 4ckjA-2gcdA:
27.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4I22_A_IREA9001_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		8 / 12 GLY A  35
VAL A  42
ALA A  55
MET A 105
GLY A 110
ASP A 114
LEU A 158
ASP A 169
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 3.7A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.3A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.89A 4i22A-2gcdA:
18.7		 4i22A-2gcdA:
26.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4I41_A_MIXA500_1
(SERINE/THREONINE-PRO
TEIN KINASE PIM-1)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		8 / 12 VAL A  42
ALA A  55
ILE A  89
ASP A 151
LYS A 153
ASN A 156
LEU A 158
ASP A 169
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
None
STU  A 400 (-4.4A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.60A 4i41A-2gcdA:
26.6		 4i41A-2gcdA:
28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4L9I_A_8PRA601_1
(RHODOPSIN KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		4 / 7 VAL A  42
ALA A  55
MET A 105
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 3.7A)
STU  A 400 ( 4.6A)
 0.59A 4l9iA-2gcdA:
11.1		 4l9iA-2gcdA:
23.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4L9I_B_8PRB601_1
(RHODOPSIN KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 8 GLY A  37
VAL A  42
ALA A  55
LYS A  57
MET A 105
 None
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 ( 3.7A)
 0.50A 4l9iB-2gcdA:
27.7		 4l9iB-2gcdA:
23.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4L9I_B_8PRB601_1
(RHODOPSIN KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 8 GLY A  37
VAL A  42
ALA A  55
MET A 105
LEU A 158
 None
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 3.7A)
STU  A 400 ( 4.6A)
 0.77A 4l9iB-2gcdA:
27.7		 4l9iB-2gcdA:
23.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4OGR_A_ADNA401_1
(CYCLIN-DEPENDENT
KINASE 9)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 8 ILE A  34
VAL A  42
ALA A  55
ASN A 156
LEU A 158
ASP A 169
 STU  A 400 (-4.2A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-4.4A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.42A 4ogrA-2gcdA:
28.6		 4ogrA-2gcdA:
28.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4OGR_E_ADNE401_1
(CYCLIN-DEPENDENT
KINASE 9)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 7 GLY A  35
ALA A  55
CYH A 108
ASN A 156
LEU A 158
ASP A 169
 STU  A 400 (-3.3A)
STU  A 400 (-3.2A)
STU  A 400 (-4.0A)
STU  A 400 (-4.4A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.63A 4ogrE-2gcdA:
27.7		 4ogrE-2gcdA:
28.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4OGR_I_ADNI401_1
(CYCLIN-DEPENDENT
KINASE 9)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 9 ILE A  34
VAL A  42
ALA A  55
CYH A 108
ASN A 156
LEU A 158
ASP A 169
 STU  A 400 (-4.2A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-4.0A)
STU  A 400 (-4.4A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.44A 4ogrI-2gcdA:
28.5		 4ogrI-2gcdA:
28.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4OTI_A_MI1A1001_1
(SERINE/THREONINE-PRO
TEIN KINASE N1)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 GLY A  35
GLY A  37
GLY A  40
VAL A  42
ALA A  55
LYS A  57
LEU A 158
 STU  A 400 (-3.3A)
None
None
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 ( 4.6A)
 0.57A 4otiA-2gcdA:
23.0		 4otiA-2gcdA:
26.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QMN_A_DB8A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ILE A  34
ALA A  55
LYS A  57
GLU A  76
TYR A 107
LEU A 158
ASP A 169
 STU  A 400 (-4.2A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 (-4.5A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.78A 4qmnA-2gcdA:
36.3		 4qmnA-2gcdA:
42.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QMS_A_1N1A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 11 ILE A  34
ALA A  55
LYS A  57
GLU A  76
TYR A 107
LEU A 158
ASP A 169
 STU  A 400 (-4.2A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 (-4.5A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.93A 4qmsA-2gcdA:
36.5		 4qmsA-2gcdA:
42.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QMZ_A_B49A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ILE A  34
GLY A  35
VAL A  42
ALA A  55
MET A 105
TYR A 107
LEU A 158
 STU  A 400 (-4.2A)
STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 3.7A)
STU  A 400 (-4.5A)
STU  A 400 ( 4.6A)
 0.61A 4qmzA-2gcdA:
36.7		 4qmzA-2gcdA:
42.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QRC_A_0LIA802_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 8 VAL A  42
LYS A  57
ILE A  89
HIS A 149
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 ( 4.5A)
STU  A 400 ( 4.5A)
None
STU  A 400 ( 4.6A)
 0.43A 4qrcA-2gcdA:
25.4		 4qrcA-2gcdA:
28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4R7I_A_STIA1001_1
(MACROPHAGE
COLONY-STIMULATING
FACTOR 1 RECEPTOR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 VAL A  42
ALA A  55
GLU A  76
CYH A 108
LEU A 158
GLY A 168
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
None
STU  A 400 (-4.0A)
STU  A 400 ( 4.6A)
None
 0.47A 4r7iA-2gcdA:
24.6		 4r7iA-2gcdA:
25.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZ7_A_1E8A901_1
(CGMP-DEPENDENT
PROTEIN KINASE,
PUTATIVE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 10 ILE A  34
ALA A  55
LYS A  57
ILE A  89
LEU A 158
 STU  A 400 (-4.2A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 ( 4.5A)
STU  A 400 ( 4.6A)
 0.85A 4rz7A-2gcdA:
10.6		 4rz7A-2gcdA:
17.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 VAL A  42
ALA A  55
CYH A 108
SER A 111
GLY A 168
GLY A 171
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-4.0A)
STU  A 400 (-3.3A)
None
None
 1.40A 4rzvB-2gcdA:
24.9		 4rzvB-2gcdA:
30.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		8 / 11 GLY A  37
VAL A  42
ALA A  55
TYR A 107
GLY A 110
ASN A 156
LEU A 158
ASP A 169
 None
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-4.5A)
STU  A 400 (-3.4A)
STU  A 400 (-4.4A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.70A 4u5jA-2gcdA:
27.7		 4u5jA-2gcdA:
30.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V01_A_0LIA1776_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 9 VAL A  42
LYS A  57
ILE A  89
TYR A 107
ARG A 150
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 ( 4.5A)
STU  A 400 ( 4.5A)
STU  A 400 (-4.5A)
SEP  A 181 ( 2.9A)
STU  A 400 ( 4.6A)
 0.69A 4v01A-2gcdA:
24.5		 4v01A-2gcdA:
26.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V04_A_0LIA1772_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		4 / 8 LYS A  57
ILE A  89
TYR A 107
LEU A 158
 STU  A 400 ( 4.5A)
STU  A 400 ( 4.5A)
STU  A 400 (-4.5A)
STU  A 400 ( 4.6A)
 0.55A 4v04A-2gcdA:
24.2		 4v04A-2gcdA:
26.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V04_B_0LIB1771_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 10 VAL A  42
LYS A  57
ILE A  89
TYR A 107
ARG A 150
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 ( 4.5A)
STU  A 400 ( 4.5A)
STU  A 400 (-4.5A)
SEP  A 181 ( 2.9A)
STU  A 400 ( 4.6A)
 0.88A 4v04B-2gcdA:
24.9		 4v04B-2gcdA:
26.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XV2_A_P06A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 VAL A  42
ALA A  55
CYH A 108
GLY A 168
ASP A 169
PHE A 170
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-4.0A)
None
STU  A 400 (-3.6A)
None
 0.69A 4xv2A-2gcdA:
25.5		 4xv2A-2gcdA:
30.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XV2_B_P06B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 ALA A  55
LEU A  80
CYH A 108
GLY A 168
ASP A 169
PHE A 170
 STU  A 400 (-3.2A)
None
STU  A 400 (-4.0A)
None
STU  A 400 (-3.6A)
None
 0.79A 4xv2B-2gcdA:
25.8		 4xv2B-2gcdA:
30.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5AAA_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 9 VAL A  42
ALA A  55
GLY A 110
LEU A 158
GLY A 168
ASP A 169
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
None
STU  A 400 (-3.6A)
 0.66A 5aaaA-2gcdA:
26.4		 5aaaA-2gcdA:
28.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5AJQ_B_DB8B800_1
(SERINE/THREONINE-PRO
TEIN KINASE 10)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 10 ALA A  55
CYH A 108
GLY A 110
LEU A 158
ASP A 169
 STU  A 400 (-3.2A)
STU  A 400 (-4.0A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.45A 5ajqB-2gcdA:
25.5		 5ajqB-2gcdA:
36.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BVW_A_1N1A1009_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		8 / 12 VAL A  42
ALA A  55
LYS A  57
GLU A  76
ILE A  89
TYR A 107
GLY A 110
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 ( 4.5A)
STU  A 400 (-4.5A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.72A 5bvwA-2gcdA:
24.3		 5bvwA-2gcdA:
28.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5CSW_A_P06A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 VAL A  42
ALA A  55
LEU A  80
CYH A 108
GLY A 168
PHE A 170
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
None
STU  A 400 (-4.0A)
None
None
 0.61A 5cswA-2gcdA:
25.3		 5cswA-2gcdA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5CSW_B_P06B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 VAL A  42
ALA A  55
LEU A  80
CYH A 108
GLY A 168
PHE A 170
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
None
STU  A 400 (-4.0A)
None
None
 0.66A 5cswB-2gcdA:
25.3		 5cswB-2gcdA:
30.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5EAJ_B_FOLB201_0
(DIHYDROFOLATE
REDUCTASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 12 ILE A 213
LEU A 245
THR A 132
ILE A 128
PRO A 122
 None
 0.93A 5eajB-2gcdA:
undetectable		 5eajB-2gcdA:
20.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5H2U_B_1N1B501_1
(PROTEIN-TYROSINE
KINASE 6)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 VAL A  42
ALA A  55
GLY A 110
LEU A 158
GLY A 168
ASP A 169
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
None
STU  A 400 (-3.6A)
 0.78A 5h2uB-2gcdA:
25.3		 5h2uB-2gcdA:
28.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 VAL A  42
ALA A  55
ILE A  89
TYR A 107
PHE A 170
GLY A 171
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 (-4.5A)
None
None
 1.03A 5hesA-2gcdA:
24.4		 5hesA-2gcdA:
27.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HI2_A_BAXA801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ALA A  55
LYS A  57
GLU A  76
CYH A 108
LEU A 142
HIS A 149
GLY A 168
 STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 (-4.0A)
None
None
None
 0.76A 5hi2A-2gcdA:
25.4		 5hi2A-2gcdA:
30.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HI2_A_BAXA801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ALA A  55
LYS A  57
GLU A  76
LEU A  80
LEU A 142
HIS A 149
GLY A 168
 STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
None
None
None
None
 0.87A 5hi2A-2gcdA:
25.4		 5hi2A-2gcdA:
30.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HIE_B_P06B801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 7 ILE A  34
GLY A  35
CYH A 108
ASP A 169
PHE A 170
 STU  A 400 (-4.2A)
STU  A 400 (-3.3A)
STU  A 400 (-4.0A)
STU  A 400 (-3.6A)
None
 1.10A 5hieB-2gcdA:
24.6		 5hieB-2gcdA:
30.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HIE_D_P06D801_2
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 8 ILE A  34
GLY A  35
CYH A 108
ASP A 169
PHE A 170
 STU  A 400 (-4.2A)
STU  A 400 (-3.3A)
STU  A 400 (-4.0A)
STU  A 400 (-3.6A)
None
 1.08A 5hieD-2gcdA:
24.8		 5hieD-2gcdA:
30.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5I9X_A_DB8A1001_1
(EPHRIN TYPE-A
RECEPTOR 2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ILE A  34
ALA A  55
ILE A  89
TYR A 107
GLY A 110
GLU A 117
LEU A 158
 STU  A 400 (-4.2A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 (-4.5A)
STU  A 400 (-3.4A)
None
STU  A 400 ( 4.6A)
 1.39A 5i9xA-2gcdA:
25.5		 5i9xA-2gcdA:
29.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5I9X_A_DB8A1001_1
(EPHRIN TYPE-A
RECEPTOR 2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ILE A  34
ALA A  55
LYS A  57
ILE A  89
TYR A 107
GLY A 110
LEU A 158
 STU  A 400 (-4.2A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 ( 4.5A)
STU  A 400 (-4.5A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.58A 5i9xA-2gcdA:
25.5		 5i9xA-2gcdA:
29.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5IKR_A_ID8A601_1
(PROSTAGLANDIN G/H
SYNTHASE 2)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 12 LEU A 159
VAL A 131
GLY A 134
ALA A 135
LEU A 167
 None
 1.15A 5ikrA-2gcdA:
undetectable		 5ikrA-2gcdA:
20.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5IZJ_F_AZ1F2_1
(CAMP-DEPENDENT
PROTEIN KINASE
CATALYTIC SUBUNIT
ALPHA
47P-AZ1-DAR-DAR-DAR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 7 GLY A  35
GLY A  37
SER A  38
GLY A  40
VAL A  42
 STU  A 400 (-3.3A)
None
None
None
STU  A 400 ( 4.8A)
 0.69A 5izjB-2gcdA:
27.7		 5izjB-2gcdA:
26.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J5X_B_AZ1B2_1
(CAMP-DEPENDENT
PROTEIN KINASE
CATALYTIC SUBUNIT
ALPHA
47P-AZ1-DAL-DAR-DAR-
DAR-DAR)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		4 / 7 GLY A  35
GLY A  37
SER A  38
VAL A  42
 STU  A 400 (-3.3A)
None
None
STU  A 400 ( 4.8A)
 0.49A 5j5xA-2gcdA:
28.1		 5j5xA-2gcdA:
26.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J7W_C_MTXC402_1
(THYMIDYLATE SYNTHASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 12 LEU A 164
LEU A 123
GLY A 110
ILE A 157
ALA A 154
 None
None
STU  A 400 (-3.4A)
None
None
 0.99A 5j7wC-2gcdA:
undetectable		 5j7wC-2gcdA:
21.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LW1_B_ADNB401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 8)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 9 ILE A  34
GLY A  35
VAL A  42
ALA A  55
ILE A  89
MET A 105
 STU  A 400 (-4.2A)
STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 ( 3.7A)
 0.39A 5lw1B-2gcdA:
23.3		 5lw1B-2gcdA:
12.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LW1_E_ADNE401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 8)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		5 / 10 GLY A  35
VAL A  42
ALA A  55
ILE A  89
MET A 105
 STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
STU  A 400 ( 3.7A)
 0.51A 5lw1E-2gcdA:
17.4		 5lw1E-2gcdA:
12.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MAF_A_XINA403_1
(MATERNAL EMBRYONIC
LEUCINE ZIPPER
KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ILE A  34
GLY A  35
VAL A  42
ALA A  55
GLU A  76
TYR A 107
GLY A 110
 STU  A 400 (-4.2A)
STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
None
STU  A 400 (-4.5A)
STU  A 400 (-3.4A)
 0.78A 5mafA-2gcdA:
28.2		 5mafA-2gcdA:
14.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MAF_A_XINA403_1
(MATERNAL EMBRYONIC
LEUCINE ZIPPER
KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ILE A  34
GLY A  35
VAL A  42
ALA A  55
LYS A  57
GLU A  76
TYR A 107
 STU  A 400 (-4.2A)
STU  A 400 (-3.3A)
STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 (-4.5A)
 0.71A 5mafA-2gcdA:
28.2		 5mafA-2gcdA:
14.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5OWR_A_1N1A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 10)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 8 ALA A  55
GLU A  76
CYH A 108
LEU A 158
ASP A 169
VAL A 301
 STU  A 400 (-3.2A)
None
STU  A 400 (-4.0A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
None
 0.52A 5owrA-2gcdA:
29.3		 5owrA-2gcdA:
36.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VC3_A_DB8A601_1
(WEE1-LIKE PROTEIN
KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ALA A  55
GLU A  76
TYR A 107
CYH A 108
GLY A 110
ASP A 114
ASP A 169
 STU  A 400 (-3.2A)
None
STU  A 400 (-4.5A)
STU  A 400 (-4.0A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.3A)
STU  A 400 (-3.6A)
 0.85A 5vc3A-2gcdA:
27.4		 5vc3A-2gcdA:
23.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VC3_A_DB8A601_1
(WEE1-LIKE PROTEIN
KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ILE A  34
ALA A  55
GLU A  76
TYR A 107
CYH A 108
GLY A 110
ASP A 114
 STU  A 400 (-4.2A)
STU  A 400 (-3.2A)
None
STU  A 400 (-4.5A)
STU  A 400 (-4.0A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.3A)
 1.09A 5vc3A-2gcdA:
27.4		 5vc3A-2gcdA:
23.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VC3_A_DB8A601_1
(WEE1-LIKE PROTEIN
KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ILE A  34
GLY A  35
ALA A  55
TYR A 107
CYH A 108
GLY A 110
ASP A 114
 STU  A 400 (-4.2A)
STU  A 400 (-3.3A)
STU  A 400 (-3.2A)
STU  A 400 (-4.5A)
STU  A 400 (-4.0A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.3A)
 0.79A 5vc3A-2gcdA:
27.4		 5vc3A-2gcdA:
23.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5VCV_A_1N1A404_1
(MEMBRANE-ASSOCIATED
TYROSINE- AND
THREONINE-SPECIFIC
CDC2-INHIBITORY
KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 ALA A  55
LYS A  57
GLU A  76
LEU A 103
GLY A 110
GLY A 168
 STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
None
STU  A 400 (-3.4A)
None
 0.95A 5vcvA-2gcdA:
28.2		 5vcvA-2gcdA:
30.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5VCY_A_DB8A401_1
(MEMBRANE-ASSOCIATED
TYROSINE- AND
THREONINE-SPECIFIC
CDC2-INHIBITORY
KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		6 / 12 VAL A  42
ALA A  55
LYS A  57
GLU A  76
CYH A 108
GLY A 110
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 (-4.0A)
STU  A 400 (-3.4A)
 0.98A 5vcyA-2gcdA:
28.1		 5vcyA-2gcdA:
30.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 VAL A  42
ALA A  55
LYS A  57
GLU A  76
CYH A 108
GLY A 110
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 (-4.0A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.50A 5y7zA-2gcdA:
25.6		 5y7zA-2gcdA:
27.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 VAL A  42
ALA A  55
LYS A  57
GLU A  76
CYH A 108
GLY A 110
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 (-4.0A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.50A 5y7zA-2gcdA:
25.6		 5y7zA-2gcdA:
9.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_B_IREB401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		7 / 12 ALA A  55
LYS A  57
GLU A  76
CYH A 108
GLY A 110
LEU A 158
ASP A 169
 STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 (-4.0A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.45A 5y7zB-2gcdA:
18.0		 5y7zB-2gcdA:
9.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y80_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		8 / 12 VAL A  42
ALA A  55
LYS A  57
GLU A  76
CYH A 108
GLY A 110
LEU A 158
ASP A 169
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 (-4.0A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.45A 5y80A-2gcdA:
24.3		 5y80A-2gcdA:
9.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5ZV2_B_LEVB801_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		3 / 3 TYR A 107
LEU A 158
ASP A 169
 STU  A 400 (-4.5A)
STU  A 400 ( 4.6A)
STU  A 400 (-3.6A)
 0.79A 5zv2B-2gcdA:
24.5		 5zv2B-2gcdA:
14.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BSD_A_1N1A901_0
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2gcd SERINE/THREONINE-PRO
TEIN KINASE TAO2
(Rattus
norvegicus) 		8 / 12 VAL A  42
ALA A  55
LYS A  57
GLU A  76
ILE A  89
TYR A 107
GLY A 110
LEU A 158
 STU  A 400 ( 4.8A)
STU  A 400 (-3.2A)
STU  A 400 ( 4.5A)
None
STU  A 400 ( 4.5A)
STU  A 400 (-4.5A)
STU  A 400 (-3.4A)
STU  A 400 ( 4.6A)
 0.68A 6bsdA-2gcdA:
24.0		 6bsdA-2gcdA:
14.87